The mechanisms mediating the pulmonary vascular remodelling that occurs in pulmonary arterial hypertension (PAH) remain unclear. Here, Shu et al. identify high serum IgE levels in patients with PAH and in mouse and rat models of pulmonary hypertension (PH). Antibody-mediated IgE blockade prevented the development of PH in mice and rats. Mechanistically, IgE promoted vascular muscularization by binding with FcεRIα, activating mast cells and promoting the release of IL-6 and IL-13. The clinically approved anti-IgE monoclonal antibody omalizumab ameliorated established PH in rats.
- IN BRIEF
Inhibiting IgE in pulmonary hypertension
Nature Reviews Drug Discovery 21, 636 (2022)
doi: https://doi.org/10.1038/d41573-022-00131-0
References
Shu, T. et al. Inhibition of immunoglobulin E attenuates pulmonary hypertension. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-022-00095-9 (2022)
